Chemotherapy of Lung Cancer

New England Journal of Medicine

Volumn 327, Issue 20, 1992, Pages 1434-1441

  Wood, Alastair J j ^a   Ihde, Daniel C ^b  

^a National Cancer Institute ^*

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; TENIPOSIDE; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DRUG THERAPY, COMBINATION; HUMAN; LUNG NEOPLASMS;

EID: 0026440636     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199211123272006     Document Type: Review

References (107)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1991. CA Cancer J Clin 1991; 41: 19–36.
2. Ries LAG, Hankey BF, Miller BA, Hartman AM, Edwards BK. Cancer statistics review 1973–1988. Bethesda, Md.: National Cancer Institute, 1991. (NIH publication no. 91–2789.)
3. American Joint Committee on Cancer. Lung. In: Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for staging of cancer. 3rd ed. Philadelphia: J.B. Lippincott, 1988:115–21.
4. Minna JD, Pass H, Glatstein E, Ihde DC. Cancer of the lung. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 3rd ed. Vol. 1. Philadelphia: J.B. Lippincott, 1989:591–705.
5. Ihde DC, Minna JD. Non-small cell lung cancer. I. Biology, diagnosis, and staging. Curr Probl Cancer 1991; 15: 61–104.
6. Mountain CF. Therapy of stage I and stage II non-small cell lung cancer. Semin Oncol 1983; 10: 71–80.
7. Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small cell lung cancer: a guide for future studies. J Clin Oncol 1984; 2: 1352–8.
8. The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected Stage II and Stage III epidermoid cancer of the lung. N Engl J Med 1986; 315: 1377–81.
9. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. Cancer 1987; 59: 1874–81.
10. Ihde DC, Minna JD. Non-small cell lung cancer. II. Treatment. Curr Probl Cancer 1991; 15: 105–54.
11. Østerlind K, Hansen HH, Hansen M, Dombernowsky P. Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer. J Clin Oncol 1986; 4: 1044–52.
12. Johnson BE, Grayson J, Makuch RW, et al. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol 1990; 8: 396–401.
13. Spiro SG, Shah S, Harper PG, Tobias JS, Geddes DM, Souhami RL. Treatment of obstruction of the superior vena cava by combination chemotherapy with and without irradiation in small-cell carcinoma of the bronchus. Thorax 1983; 38: 501–5.
14. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 1989; 7: 916–22.
15. Green RA, Humphrey E, Close H, Patno ME. Alkylating agents in bronchogenic carcinoma. Am J Med 1969; 46: 516–25.
16. Carney DN, Grogan L, Smit EF, Harford P, Berendsen HH, Postmus PE. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 1990; 17: Suppl 2: 49–53.
17. Smith IE, Harland SJ, Robinson BA, et al. Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 1985; 69: 43–6.
18. Grant SC, Gralla RJ, Kris MG, Orazem J, Kitsis EA. Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol 1992; 10: 484–98.
19. Bork E, Ersbøll J, Dombernowsky P, Bergman B, Hansen M, Hansen HH. Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. J Clin Oncol 1991; 9: 1627–31.
20. Edmonson JH, Lagakos SW, Selawry OS, et al. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 1976; 60: 925–32.
21. Lowenbraun S, Bartolucci A, Smalley RV, Lynn M, Krauss S, Durant JR. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 1979; 44: 406–13.
22. Alberto P, Brunner KW, Martz G, Obrecht JP, Sonntag RW. Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine. Cancer 1976; 38: 2208–16.
23. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer: report to the Medical Research Council by its Lung Cancer Working Party. Respir Med 1989; 83: 51–8.
24. Lowenbraun S, Birch R, Buchanan R, et al. Combination chemotherapy in small cell lung carcinoma: a randomized study of two intensive regimens. Cancer 1984; 54: 2344–50.
25. Jackson DV Jr, Case LD, Zekan PJ, et al. Improvement of long-term survival in extensive small-cell lung cancer. J Clin Oncol 1988; 6: 1161–9.
26. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855–61.
27. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282–91.
28. Cohen MH, Creaven PJ, Fossieck BE Jr, et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977; 61: 349–54.
29. Mehta C, Vogl SE. High-dose cyclophosphamide in the induction therapy of small cell lung cancer: minor improvements in rate of remission and survival. Proc Am Assoc Cancer Res 1982; 23: 155. abstract.
30. Johnson DH, Einhorn LH, Birch R, et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987; 5: 1731–8.
31. Ihde DC, Mulshine JL, Kramer BS, et al. Randomized trial of high vs. standard dose etoposide (VP16) and cisplatin in extensive stage small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1991; 10: 240. abstract.
32. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–70.
33. Johnson DH, DeLeo MJ, Hande KR, Wolff SN, Hinsworth JD, Greco FA. High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer. J Clin Oncol 1987; 5: 703–9.
34. Brower M, Ihde DC, Johnston-Early A, et al. Treatment of extensive stage small cell bronchogenic carcinoma: effects of variation in intensity of induction chemotherapy. Am J Med 1983; 75: 993–1000.
35. Valdivieso M, Cabanillas F, Keating M, et al. Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units. Am J Med 1984; 76: 405–12.
36. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991; 9: 499–508.
37. Spitzer G, Farha P, Valdivieso M, et al. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol 1986; 4: 4–13.
38. Ihde DC, Deisseroth AB, Lichter AS, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol 1986; 4: 1443–54.
39. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5: 1864–73.
40. Cohen MH, Ihde DC, Bunn PA Jr, et al. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 1979; 63: 163–70.
41. Goldie JH, Coldman AJ. Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–49.
42. Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990; 8: 230–40.
43. Elliott JA, Østerlind K, Hansen HH. Cyclic alternating 'non-cross-resistant' chemotherapy in the management of small cell anaplastic carcinoma of the lung. Cancer Treat Rev 1984; 11: 103–13.
44. Østerlind K, Sörenson S, Hansen HH, et al. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res 1983; 43: 6085–9.
45. Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: a multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987; 107: 451–8.
46. Einhorn LH, Crawford J, Birch R, Omura G, Johnson DH, Greco FA. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 1988; 6: 451–6.
47. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer: report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1989; 59: 584–90.
48. Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989; 59: 578–83.
49. Splinter TAW. EORTC 08825-induction vs induction plus maintenance chemotherapy (CT) in small cell lung cancer (SCLC): definitive evaluation. Proc Am Soc Clin Oncol 1988; 7: 202. abstract.
50. Batist G, Carney DN, Cowan KH, et al. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol 1986; 4: 982–6.
51. Giaccone G, Donadio M, Bonardi G, Testore F, Calciati A. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988; 6: 1264–70.
52. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990; 8: 1613–7.
53. Bunn PA Jr, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: a prospective, randomized trial. Ann Intern Med 1987; 106: 655–62.
54. Perez CA, Einhorn L, Oldham RK, et al. Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J Clin Oncol 1984; 2: 1200–8.
55. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316: 912–8.
56. Johnson DH, Arriagada R, Ihde DC, et al. Meta-analysis of randomized trials evaluating the role of thoracic radiotherapy in limited-stage small cell lung cancer. Proc Am Soc Clin Oncol 1992; 11: 288. abstract.
57. McCracken JD, Janaki LM, Crowley JJ, et al. Concurrent chemotherapy/ radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group study. J Clin Oncol 1990; 8: 892–8.
58. Murray N, Coy P, Pater J, et al. The importance of timing for thoracic irradiation (TI) in the combined modality treatment of limited stage small cell lung cancer (LSCLC). Proc Am Soc Clin Oncol 1991; 10: 243. abstract.
59. Durrani KR, Berry RJ, Ellis F, Ridehalgh FR, Black JM, Hamilton WS. Comparison of treatment policies in inoperable bronchial carcinoma. Lancet 1971; 1: 715–9.
60. Shields TW, Humphrey EW, Eastridge CE. Keehn RJ. Adjuvant cancer chemotherapy after resection of carcinoma of the lung. Cancer 1977; 40: 2057–62.
61. Shields TW, Higgins GA Jr, Humphrey EW, Matthews MJ, Keehn RJ. Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung. Cancer 1982; 50: 1713–21.
62. Petrovich Z, Ohanian M, Cox J. Clinical research on the treatment of locally advanced lung cancer: final report of VALG Protocol 13 Limited. Cancer 1978; 42: 1129–34.
63. Davis S, Pandya MR, Rambotti P. Single-agent and combination chemotherapy for extensive non-small cell carcinomas of the lung. Cancer Treat Rep 1980; 64: 685–8.
64. Einhorn LH, Williams SD, Stevens EE, Bond WH, Chenoweth L. Random prospective study of cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non small cell lung cancer. Cancer Treat Rep 1982; 66: 2005–11.
65. Sørensen JB, Hensen HH, Dombernowsky P, et al. Chemotherapy for adenocarcinoma of the lung (WHO III): a randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs. J Clin Oncol 1987; 5: 1169–77.
66. Eagan RT, Ingle JN, Frytak S, et al. Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. Cancer Treat Rep 1977; 61: 1339–45.
67. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell-lung cancer treated with combination chemotherapy. J Clin Oncol 1986; 4: 1604–14.
68. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4: 702–9.
69. Elliott JA, Ahmedzai S, Hole D, et al. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol 1984; 20: 1025–32.
70. Luedke DW, Einhorn L, Omura GA, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol 1990; 8: 886–91.
71. Rosso R, Salvati F, Ardizzoni A, et al. Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer: results of a prospective randomized FONICAP trial. Cancer 1990; 65: 130–4.
72. Veronesi A, Magri MD, Tirelli U, et al. Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide: a randomized study. Am J Clin Oncol 1988; 11: 566–71.
73. Donnadieu N, Paesmans M, Sculier JP. Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature. Lung Cancer 1991; 7: 243–52.
74. Gandara DR, Tanaka MT, Crowley J, Livingston RB. Comparison of standard dose cisplatin, high dose cisplatin, and high dose cisplatin plus mitomycin in metastatic non small cell lung cancer: preliminary results of a phase III study. Proc Am Soc Clin Oncol 1991; 10: 246. abstract.
75. Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95: 414–20.
76. Klastersky J, Sculier JP, Ravez P, et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 1986; 4: 1780–6.
77. Davis S, Rambotti P, Park YK. Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung. Cancer Treat Rep 1981; 65: 955–8.
78. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602–13.
79. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer — report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633–41.
80. Woods RL, Williams CJ, Levi J, et al. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990; 61: 608–11.
81. Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991; 9: 1453–61.
82. Kaasa S, Lund E, Thorud E, Hatlevoll R, Høst H. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 1991; 67: 2443–7.
83. Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer: does chemotherapy make a difference? Cancer 1989; 63: 1271–8.
84. Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990; 113: 33–8.
85. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small-cell lung cancer. N Engl J Med 1990; 323: 940–5.
86. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non—small-cell lung cancer. N Engl J Med 1992; 326: 524–30.
87. Le Chevalier T, Amagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417–23.
88. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992; 84: 58.
89. Mattson K, Holsti LR, Holsti P, et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988; 24: 477–82.
90. Martini N, Flehinger BJ, Zaman MB, Beattie EJ Jr. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 1983; 198: 386–97.
91. Martini N, Kris MG, Gralla RJ, et al. The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0). Ann Thorac Surg 1988; 45: 370–9.
92. Skarin A, Jochelson M, Sheldon T, et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989; 40: 266–74.
93. Taylor SG IV, Trybula M, Bonomi PD, et al. Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer. Ann Thorac Surg 1987; 43: 87–91.
94. Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group. J Natl Cancer Inst 1991; 83: 266–73.
95. Holmes EC, Gail M. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 1986; 4: 710–5.
96. The Lung Cancer Study Group. The benefit of adjuvant treatment for resected locally advanced non—small-cell lung cancer. J Clin Oncol 1988; 6: 9–17.
97. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986; 4: 14–22.
98. Kris MG, Gralla RJ, Potanovich LM, Marks LD, Heelan RT. Assessment of pretreatment symptoms and improvement after EDAM+mitomycin+ vinblastine in patients with inoperable non-small cell lung cancer. Proc Am Soc Clin Oncol 1990; 9: 229. abstract.
99. Viallet J, Ihde DC. Small cell carcinoma of the lung: clinical and biologic aspects. Crit Rev Oncol Hematol 1991; 11: 109–35.
100. Chang A, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol in patients with stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. Proc Am Soc Clin Oncol 1992; 11: 293. abstract.
101. Murphy WK, Winn RJ, Fossella FV, et al. A phase II study of taxol (NSC-125973) in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1992; 11: 294. abstract.
102. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10: 16–20.
103. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83: 757–66.
104. Chabner BA. In defense of cell-line screening. J Natl Cancer Inst 1990; 82: 1083–5.
105. Johnson RK. Screening methods in antineoplastic drug discovery. J Natl Cancer Inst 1990; 82: 1082–3.
106. Sikic BI. Anticancer drug discovery. J Natl Cancer Inst 1991; 83: 738–40.
107. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795–801.